Edition:
India

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

1.10USD
14 Dec 2018
Change (% chg)

$0.05 (+4.76%)
Prev Close
$1.05
Open
$1.05
Day's High
$1.10
Day's Low
$1.04
Volume
41,094
Avg. Vol
287,188
52-wk High
$5.86
52-wk Low
$0.70

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2018 Sep '18 30.33 -1.316
Jun '18 31.90 -1.667
Mar '18 27.48 -1.755
FY 2017 Dec '17 38.91 -1.316
Sep '17 28.67 -2.668
Jun '17 40.88 -1.152
Mar '17 29.98 -1.670
FY 2016 Dec '16 13.57 -1.482
Sep '16 0.00 -0.562
Jun '16 0.00 -0.485
Mar '16 0.00 -2.072
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Dec-18 1 40.90 40.90 40.90 --
Year Ending Dec-18 1 130.60 130.60 130.60 155.00
Year Ending Dec-19 1 146.90 146.90 146.90 189.20
Earnings (per share)
Quarter Ending Dec-18 1 -0.90 -0.90 -0.90 --
Year Ending Dec-18 1 -5.63 -5.63 -5.63 -3.40
Year Ending Dec-19 1 -3.64 -3.64 -3.64 -0.43
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

Dividends

Growth Rates

Financial Strength

Profitability Ratios

Efficiency

Management Effectiveness

  1 Year 3 Year 5 Year
Sales % -- -- --
EPS (TTM) % -112.47 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Novelion Therapeutics Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week -0.42 -3.86 76 --
13 Week -24.41 -28.09 30 --
26 Week -33.93 -38.95 38 --
52 Week -31.41 -41.87 58 --
YTD -16.51 -26.68 59 --
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 80.19%
# of Holders: 59
Total Shares Held: 15,182,572
3 Mo. Net Change: 870,902
# New Positions: 6
# Closed Positions: 11
# Increased Positions: 14
# Reduced Positions: 27
# Net Buyers: -13
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.